University of Arizona Professor Received $1.9 Million Grant
The funding supports a five-year project to develop synthetic drug carriers modeled after human red blood cells.
Updated on Oct. 5, 2026 in Life Sciences
Live Poll
Should medical research prioritize developing synthetic drug delivery systems that improve treatment accuracy and safety?
The National Institute of General Medical Sciences has awarded a $1.9 million grant to Minkyu Kim, an associate professor at the University of Arizona. Kim and his research group aim to design synthetic microcarriers that mimic the protein networks of red blood cells.
Why it matters
Conventional drug delivery systems are often cleared from the body too quickly by the immune system. This research seeks to extend the longevity of these carriers, potentially enabling more precise delivery and reduced dosage frequency for patients.
The study focuses on replicating the cytoskeleton protein network of red blood cells to create synthetic microcarriers. These units are engineered to deform and recover their shape to effectively navigate narrow blood vessels.
The players
Minkyu Kim
He is an associate professor of materials science and biomedical engineering at the University of Arizona.
National Institute of General Medical Sciences
It is a federal agency that supports research into basic biological processes to better understand disease states.
Kim Research Group
This University of Arizona lab focuses on materials science and biomedical engineering innovations.
The details
The Kim Research Group at the University of Arizona is developing these carriers to withstand the body's natural filtering processes. By imitating the physical properties of real blood cells, the team hopes to improve how therapeutic agents circulate through the bloodstream.
Timeline
Over the next five years, the research project will conduct development and testing.
The Big Picture
This research follows a pattern set by National Institute of General Medical Sciences basic research initiatives to improve therapeutic delivery. The work marks a transition toward bio-mimetic materials designed to overcome the limitations of traditional, short-lived drug delivery vehicles.
The development of long-lasting synthetic carriers could eventually lead to more convenient treatment schedules for patients requiring recurring medication. By minimizing the frequency of required doses, this technology aims to improve the quality of life for those undergoing long-term therapies.
The takeaway
Advancements in synthetic biology are increasingly focusing on mimicking the body's natural biological structures to solve complex medical delivery problems. Researchers are working to overcome the persistent challenge of immune system interference that prevents many traditional drugs from reaching their full potential.
Further reading
For more information on current innovations in the field, visit Life Sciences.
Source note: This article includes information reported by Arizona Public Media.
Live Poll
Should medical research prioritize developing synthetic drug delivery systems that improve treatment accuracy and safety?
